PRIMARY OBJECTIVES:
I. Assess feasibility of each interventional arm independently – Cohort 1A. (Arm I)
II. Detect a decline of >= 1.5 standard deviation (SD) from baseline on the Wechsler Adult Intelligence Scale (WAIS)- IV Working Memory Score or Hopkins Verbal Learning Test (HVLT) during the 36 month follow-up after surgery. (Arm II)
SECONDARY OBJECTIVES:
I. Measure changes in cognition at post-intervention and follow-up for each cohort – Cohort 1A telehealth. (Arm I)
II. Measure changes in health related quality of life (HRQOL) at post-intervention and follow-up for each cohort – Cohort 1A telehealth – as captured by Patient Reported Outcomes Measurement Information System-quality of life (PROMIS-QOL) – at 3 months and 6 months post-intervention. (Arm I)
III. Assess relationships between cognitive changes and clinical factors (molecular subtype, age, tumor location, treatment, and radiation fields when appropriate). (Arm II)
IV. Assess relationships between cognitive changes and serial magnetic resonance (MR) imaging (T2 and contrast-enhancing tumor volume, diffusion tensor imaging [DTI] scalar quantification, structural connectivity, resting-state functional magnetic resonance imaging [fMRI] connectivity). (Arm II)
V. Assess relationships between HRQOL and cognitive changes. (Arm II)
EXPLORATORY OBJECTIVES:
I. Assess relationships between cognitive and HRQOL. (Arm I)
II. Assess relationships between cognitive changes and clinical factors (molecular subtype, age, tumor location, and radiation fields when appropriate). (Arm I)
III. Assess relationships between HRQOL changes and clinical factors (molecular subtype, age, tumor location, and radiation fields when appropriate). (Arm I)
IV. Assess relationships between cognitive changes and serial MR imaging (T2 and contrast-enhancing tumor volume, DTI scalar quantification, structural connectivity, resting-state fMRI connectivity). (Arm I)
V. Identify predictive power of tumor characteristics (tumor volume, location, molecular characteristics), patient characteristics (extent of resection, treatment, and radiation fields when appropriate), imaging characteristics (e.g. fMRI, DTI changes), and decline in cognition or HRQOL. (Arm II)
OUTLINE: Patients are invited to participant in Cohort IA. Patients unable to participant in Cohort IA are randomized to Cohort II or Cohort III.
ARM I:
COHORT I (CLOSED TO ACCRUAL 02/04/2025): Patients receive standard in-person cognitive rehabilitation sessions with a neuropsychologist every 2 weeks over 1 hour each for 12 weeks.
COHORT IA (CLOSED TO ACCRUAL 02/04/2025): Patients receive telehealth cognitive rehabilitation with University of California, San Francisco (UCSF) Zoom visits with a neuropsychologist who specializes in brain tumors over 60 minutes every 2 weeks for 3 months.
COHORT II (CLOSED TO ACCRUAL 02/04/2025): Patients receive computerized cognitive rehabilitation using the ReMind app over 3 hours per week for 12 weeks.
COHORT III (CLOSED TO ACCRUAL 02/04/2025): Patients receive healthy text messages daily at random points during the week (Monday – Friday) for 12 weeks.
ARM II:
COHORT IV: Patients who receive radiation after surgery, undergo longitudinal cognitive and health related quality of life assessments prior to surgery, prior to start of radiation, at 4-6 week after radiation, 6 and 12 months after surgery, and then every 6 months for 36 months after surgery.
COHORT V: Patients who do not receive radiation after surgery, undergo longitudinal cognitive and health related quality of life assessments prior to surgery, within 1 month after surgery, 2-4 months after surgery, 6 and 12 months after surgery, and then every 6 months for 36 months after surgery.
After completion of study, patients in cohorts I-III are followed up at 3 and 9 months.
